Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD)
Source: Medical Xpress
Semaglutide boosts walking ability in diabetes patients with peripheral artery disease, clinical trial finds
get in touch with Dr. Adey and his team
at the cardiovascular clinic
cardiovascular clinic of West Tennessee
2968 North Highland Ave,
Jackson,
TN 38305
- Monday to Friday 8:00 am - 5:00 pm
